Phenylethanolamine

Phenylethanolamine

SCHEMBL296410

NCC(O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 5/20 0.57
TDP1 Q9NUW8 4/20 0.57
KDM4E B2RXH2 4/20 0.57
APEX1 P27695 3/20 0.57
TAAR1 Q96RJ0 3/20 0.57
MAPT P10636 3/20 0.57
RECQL P46063 3/20 0.57
HPGD P15428 2/20 0.57
LMNA P02545 2/20 0.57
MAPK1 P28482 2/20 0.57
ADRB2 P07550 2/20 0.57
ADRB1 P08588 2/20 0.57
ADRA2A P08913 2/20 0.57
ADRA2B P18089 2/20 0.57
ADRA2C P18825 2/20 0.57
ADRA1D P25100 2/20 0.57
CYP3A4 P08684 2/20 0.57
MEN1 O00255 1/20 0.57
ADORA3 P0DMS8 1/20 0.57
ADRB3 P13945 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenylethanolamine SCHEMBL7150657 1.00 BLM (0.57) BLMTDP1KDM4EAPEX1TAAR1
Phenylethanolamine SCHEMBL21723498 1.00 BLM (0.57) BLMTDP1KDM4EAPEX1TAAR1
Phenylethanolamine SCHEMBL25831761 1.00 BLM (0.57) BLMTDP1KDM4EAPEX1TAAR1
Phenylethanolamine SCHEMBL5888034 0.98 BLM (0.55) BLMTDP1KDM4EAPEX1TAAR1
SCHEMBL7150293 0.82 CYP3A4 (0.52) BLMTDP1KDM4EAPEX1TAAR1
SCHEMBL3389189 0.82 BLM (0.52) BLMTDP1KDM4EAPEX1TAAR1
SCHEMBL8402037 0.82 BLM (0.52) BLMTDP1KDM4EAPEX1TAAR1
SCHEMBL11516250 0.82 LMNA (0.42) BLMTDP1KDM4EAPEX1TAAR1
Hydrochloric Acid SCHEMBL15511842 0.81 BLM (0.50) BLMTDP1KDM4EAPEX1TAAR1
Hydrochloric Acid SCHEMBL15517746 0.81 BLM (0.50) BLMTDP1KDM4EAPEX1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042758-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS AGV DISCOVERY (FR) 2026-02-12 US disclosed
US-12534439-B2 Xanthohumol derivatives and methods for making and using OREGON STATE UNIVERSITY (US) 2026-01-27 US disclosed
US-12371429-B2 Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof RECREO PHARMACEUTICALS LLC (US) 2025-07-29 US disclosed
US-20250138016-A1 METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2025-05-01 US disclosed
US-20250060343-A1 METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION MATTERWORKS INC 2025-02-20 US disclosed
US-12146869-B2 Methods and compositions for analyte quantification MATTERWORKS INC (US) 2024-11-19 US disclosed
EP-4437319-A1 METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION Matterworks Inc (US) 2024-10-02 EP disclosed
US-12100484-B2 Methods and compositions for analyte quantification MATTERWORKS INC (MA) 2024-09-24 US disclosed
US-20240308997-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS AGV DISCOVERY (FR) 2024-09-19 US disclosed
US-20240270705-A1 COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE VIVIDION THERAPEUTICS, INC. 2024-08-15 US disclosed
EP-0294995-B1 OXAZOLIDIN-2-ONE DERIVATIVES AS HYPOGLYCEMIC AGENTS PFIZER INC. (US) 1992-11-11 EP disclosed
US-5153210-A Hypoglycemic agent, animal growth regulator; veterinary medicine BEECHAM GROUP P.L.C. (GB) 1992-10-06 US disclosed
US-4968707-A ANTIDIABETIC AGENTS PFIZER INC. (US) 1990-11-06 US disclosed
WO-1988009661-A1 OXAZOLIDIN-2-ONE DERIVATIVES AS HYPOGLYCEMIC AGENTS PFIZER INC. (US) 1988-12-15 WO disclosed
EP-0294995-A1 Oxazolidin-2-one derivatives as hypoglycemic agents PFIZER INC. (US) 1988-12-14 EP disclosed
EP-0236624-A2 Substituted phenyl ethanol amines, processes for their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1987-09-16 EP disclosed
EP-0171702-A1 Benzoxazinone derivatives, preparation and use BEECHAM GROUP PLC (GB) 1986-02-19 EP disclosed
US-3983133-A CNS ANTIDEPRESSANTS JANSSEN PHARMACEUTICA N.V. (BE) 1976-09-28 US disclosed
US-3963718-A CENTRAL NERVOUS SYSTEM ANTIDEPRESSANTS JANSSEN PHARMACEUTICA (BE) 1976-06-15 US disclosed
US-3947456-A ANTIDEPRESSANTS HOFFMAN-LA ROCHE INC. (US) 1976-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371429-B2 Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof CBR3, CBR1, CYP2B6 BLM 1724/4885TDP1 3375/4885KDM4E 3576/4885
US-12534439-B2 Xanthohumol derivatives and methods for making and using MT-CO1, MT-CO2, PC BLM 4590/4885TDP1 1995/4885KDM4E 1260/4885
US-20260042758-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS BRAF, RAF1, NRAS BLM 4576/4885TDP1 2497/4885KDM4E 2556/4885
US-20240270705-A1 COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE JAK2, JAK1, JAK3 BLM 3673/4885TDP1 1777/4885KDM4E 1653/4885
US-20240308997-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS MAPKAPK2, MAPK1, MAPK7 BLM 4675/4885TDP1 2442/4885KDM4E 1485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.